Insider Transactions in Q3 2024 at Bridge Bio Pharma, Inc. (BBIO)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Kkr Genetic Disorder L.P. |
SELL
Open market or private sale
|
Indirect |
5,800,000
-18.67%
|
$145,000,000
$25.75 P/Share
|
|
Aug 19
2024
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,389
-0.28%
|
$657,336
$24.76 P/Share
|
|
Aug 19
2024
|
Brian C Stephenson Secretary, Treasurer & CFO |
SELL
Open market or private sale
|
Direct |
4,155
-2.35%
|
$99,720
$24.76 P/Share
|
|
Aug 16
2024
|
Neil Kumar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,148
-0.57%
|
$675,552
$24.4 P/Share
|
|
Aug 16
2024
|
Neil Kumar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
55,537
+1.11%
|
-
|
|
Aug 16
2024
|
Brian C Stephenson Secretary, Treasurer & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,077
-12.77%
|
$313,848
$24.4 P/Share
|
|
Aug 16
2024
|
Brian C Stephenson Secretary, Treasurer & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,797
+20.12%
|
-
|
|
Aug 16
2024
|
Thomas Trimarchi President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,936
-4.33%
|
$430,464
$24.4 P/Share
|
|
Aug 06
2024
|
Thomas Trimarchi President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
19,003
+4.39%
|
-
|